Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Reform Provision Extending Angiomax Patent Would Cost $1 Bil. – CBO

Executive Summary

The Medicines Company scored a lobbying victory when a provision was tucked into patent reform legislation that would authorize the Patent and Trademark Office to accept late applications
Advertisement

Related Content

Patent Reform Legislation Introduced; Damages, Inequitable Conduct In Flux
Patent Reform Legislation Introduced; Damages, Inequitable Conduct In Flux
Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
PTO Lobbies Against Damages Award Provision in Patent Reform Bill
PTO Would Have Discretion To Accept Late Filings Under House Bill
PTO Would Have Discretion To Accept Late Filings Under House Bill
Advertisement
UsernamePublicRestriction

Register

PS049344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel